GoldenGolden
Advanced Search
Ocata Therapeutics

Ocata Therapeutics

Ocata Therapuetics was a biotechnology company focused on the development of regenerative therapeutics using stem cells in ophthalmology and other disease areas. The company was acquired by Asrellas Pharma in 2015.

History

Ocata Therapeutics, originally named Advanced Cell Technology, pioneered the first clinical investigation using human embryonic stem cell derived Retinal Pigment Epithelium (RPE) to treat retinal diseases including Stargardts Macular Degeneration (SMD) and Geographic Atrophy (GA), secondary to Age-related Macular Degeneration (AMD). The cell line generated by the company is named MA09-hRPE.

In Phase 1/2 clinical trials MA09-hRPE cells were administered in suspension form beginning in April 2011 and completed in 2017 in eye centers in the United States, United Kingdom and South Korea (Clinicaltrial.gov identifiers: UK-SMD: NCT01469832; US-SMD: NCT01345006; US-AMD: NCT01344993).

In 2014, Advanced Cell Technology changed its company name to Ocata Therapeutics.

Acquisition

In 2016, Astellas Pharma completed a tender offer to purchase Ocata Therapeutics through its subsidiary, Laurel Acquisition Inc., and Ocata Therapeutics became a subsidiary of Astellas. In 2018, the company changed its name to Astellas Institute for Regenerative Medicine (AIRM).The company’s main area of focus became the development of human embryonic stem cell-derived retinal pigmented epithelial cells (RPEs) for treatment of multiple types of macular degeneration. In a strategy to expand beyond ophthalmology and overcome the challenge of immunological rejection of transplanted cells, Astellas acquired Universal Cells and combined technologies of AIRM and Universal Cells.

Patents

Ocata Therapeutics acquired patents on the preparation and use of hemangio-colony forming cells, erythroid cells from pluripotent stem cells, platelets from pluripotent stem cells, mesenchymal stromal cells, photoreceptor cells, RPE cells and pluripotent stem cells as well as modalities to treat degenerative diseases of the retina. Biologist Robert Lanza is named as inventor on all patents and is Head of Astellas Global Regenerative Medicine and Chief Scientific Officer at the Astellas Institute for Regenerative Medicine.

Timeline

November 10, 2015
Astellas acquires Ocata Therapeutics.

SBA Awards

Patents

Products

People

Name
Role
LinkedIn

Adel Bakhtiarova

Employee

David Levy

Employee

David Levy

Investor

Jeffrey Long

Employee

Further reading

Title
Author
Link
Type
Date

Advanced Cell Technology Changes Name to Ocata Therapeutics

BusinessWire

Web

Advanced Cell Technology Changes Name to Ocata Therapeutics

BusinessWire

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.